Literature DB >> 19525408

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.

F H M Prince, M Twilt, S C M Simon, M A J van Rossum, W Armbrust, E P A H Hoppenreijs, S Kamphuis, M van Santen-Hoeufft, Y Koopman-Keemink, N M Wulffraat, R ten Cate, L W A van Suijlekom-Smit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19525408     DOI： 10.1136/ard.2008.101030

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.

Authors:  Daniel B Horton; Karen B Onel; Timothy Beukelman; Sarah Ringold
Journal:  J Rheumatol       Date:  2017-02-01       Impact factor: 4.666

2.  Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Authors:  Femke H M Prince; Lisette W A van Suijlekom-Smit
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

Review 3.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

4.  Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort.

Authors:  Antía García-Fernández; Andrea Briones-Figueroa; Laura Calvo-Sanz; África Andreu-Suárez; Alina Boteanu
Journal:  Rheumatol Int       Date:  2022-03-19       Impact factor: 2.631

Review 5.  Enthesitis-related arthritis.

Authors:  Amita Aggarwal; Durga Prasanna Misra
Journal:  Clin Rheumatol       Date:  2015-08-02       Impact factor: 2.980

Review 6.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

7.  Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment.

Authors:  Estíbaliz Iglesias; Vicenç Torrente-Segarra; Rosa Bou; Silvia Ricart; María Isabel González; Judith Sánchez; Joan Calzada; Jordi Antón
Journal:  Rheumatol Int       Date:  2013-10-26       Impact factor: 2.631

8.  Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission.

Authors:  Yubo Cai; Xiaosheng Liu; Wenming Zhang; Jianrong Xu; Lanfang Cao
Journal:  Rheumatol Int       Date:  2013-03-07       Impact factor: 2.631

9.  Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.

Authors:  Olha Halyabar; Jay Mehta; Sarah Ringold; Dax G Rumsey; Daniel B Horton
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

10.  Clinical remission in juvenile idiopathic arthritis after termination of etanercept.

Authors:  Jacek Postępski; Katarzyna Kobusińska; Edyta Olesińska; Violetta Osińska; Violetta Opoka-Winiarska
Journal:  Rheumatol Int       Date:  2012-07-21       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.